Literature DB >> 28262099

Sexual Rehabilitation After Treatment for Prostate Cancer-Part 1: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015).

Andrea Salonia1, Ganesh Adaikan2, Jacques Buvat3, Serge Carrier4, Amr El-Meliegy5, Kostas Hatzimouratidis6, Andrew McCullough7, Abraham Morgentaler8, Luiz Otavio Torres9, Mohit Khera10.   

Abstract

INTRODUCTION: Sexual dysfunction is common in patients after radical prostatectomy (RP) for prostate cancer. AIM: To provide the International Consultation for Sexual Medicine (ICSM) 2015 recommendations concerning prevention and management strategies for post-RP erectile function impairment in terms of preoperative patient characteristics and intraoperative factors that could influence erectile function recovery.
METHODS: A literature search was performed using Google and PubMed databases for English-language original and review articles published up to August 2016. MAIN OUTCOME MEASURES: Levels of evidence (LEs) and grades of recommendations (GRs) based on a thorough analysis of the literature and committee consensus.
RESULTS: Nine recommendations are provided by the ICSM 2015 committee on sexual rehabilitation after RP. Recommendation 1 states that clinicians should discuss the occurrence of postsurgical erectile dysfunction (temporary or permanent) with every candidate for RP (expert opinion, clinical principle). Recommendation 2 states that validated instruments for assessing erectile function recovery such as the International Index of Erectile Function and Expanded Prostate Cancer Index Composite questionnaires are available to monitor EF recovery after RP (LE = 1, GR = A). Recommendation 3 states there is insufficient evidence that a specific surgical technique (open vs laparoscopic vs robot-assisted radical prostatectomy) promotes better results in postoperative EF recovery (LE = 2, GR = C). Recommendation 4 states that recognized predictors of EF recovery include but are not limited to younger age, preoperative EF, and bilateral nerve-sparing surgery (LE = 2, GR = B). Recommendation 5 states that patients should be informed about key elements of the pathophysiology of postoperative erectile dysfunction, such as nerve injury and cavernous venous leak (expert opinion, clinical principle).
CONCLUSIONS: This article discusses Recommendations 1 to 5 of the ICSM 2015 committee on sexual rehabilitation after RP. Salonia A, Adaikan G, Buvat J, et al. Sexual Rehabilitation After Treatment for Prostate Cancer-Part 1: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015). J Sex Med 2017;14:285-296.
Copyright © 2017 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Erectile Function; Laparoscopic; Nerve Sparing; Prostate Cancer; Radical Prostatectomy; Rehabilitation; Robotic

Mesh:

Year:  2017        PMID: 28262099     DOI: 10.1016/j.jsxm.2016.11.325

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  14 in total

Review 1.  Focusing on sexual rehabilitation besides penile rehabilitation following radical prostatectomy is important.

Authors:  Daphné Vanderhaeghe; Maarten Albersen; Emmanuel Weyne
Journal:  Int J Impot Res       Date:  2021-03-22       Impact factor: 2.896

2.  Are We Improving Erectile Function Recovery After Radical Prostatectomy? Analysis of Patients Treated over the Last Decade.

Authors:  Paolo Capogrosso; Emily A Vertosick; Nicole E Benfante; James A Eastham; Peter J Scardino; Andrew J Vickers; John P Mulhall
Journal:  Eur Urol       Date:  2018-09-17       Impact factor: 20.096

Review 3.  Dual implantation of penile prosthesis and ATOMS® system for post-prostatectomy erectile dysfunction and urinary incontinence: a feasibility study.

Authors:  Marco Falcone; Mirko Preto; Enrico Ammirati; Gideon Blecher; Roberto Carone; Paolo Gontero; Alessandro Giammò
Journal:  Int J Impot Res       Date:  2020-06-04       Impact factor: 2.896

4.  Erectile dysfunction resulting from pelvic surgery is associated with changes in cavernosal gene expression indicative of cavernous nerve injury.

Authors:  Guillermo Villegas; Moses Tarndie Tar; Kelvin Paul Davies
Journal:  Andrologia       Date:  2021-09-12       Impact factor: 2.532

Review 5.  Prevalence of post-prostatectomy erectile dysfunction and a review of the recommended therapeutic modalities.

Authors:  Thiago Fernandes Negris Lima; Joshua Bitran; Fabio Stefano Frech; Ranjith Ramasamy
Journal:  Int J Impot Res       Date:  2020-11-17       Impact factor: 2.896

Review 6.  Sexual function outcomes following interventions for prostate cancer: are contemporary reports on functional outcomes misleading?

Authors:  Catherine E Lovegrove; Vincenzo Ficarra; Francesco Montorsi; James N'Dow; Andrea Salonia; Suks Minhas
Journal:  Int J Impot Res       Date:  2019-12-13       Impact factor: 2.896

7.  Attitude towards active surveillance: a cross-sectional survey among patients with uroandrological disorders.

Authors:  Paolo Capogrosso; Luca Boeri; Eugenio Ventimiglia; Ilenya Camozzi; Walter Cazzaniga; Francesco Chierigo; Roberta Scano; Alberto Briganti; Francesco Montorsi; Andrea Salonia
Journal:  BMJ Open       Date:  2018-08-29       Impact factor: 2.692

8.  Diagnostic and Therapeutic Workup of Erectile Dysfunction: Results From a Delphi Consensus of Andrology Experts.

Authors:  Andrea M Isidori; Bruno Giammusso; Giovanni Corona; Paolo Verze
Journal:  Sex Med       Date:  2019-06-10       Impact factor: 2.491

9.  Adherence and barriers to penile rehabilitation over 2 years following radical prostatectomy.

Authors:  Jeffrey Albaugh; Brittany Adamic; Cecilia Chang; Nicholas Kirwen; Joshua Aizen
Journal:  BMC Urol       Date:  2019-10-07       Impact factor: 2.264

10.  Scandinavian Prostate Cancer Patients' Sexual Problems and Satisfaction With Their Sex Life Following Anti-Cancer Treatment.

Authors:  Gert Martin Hald; Mie Dahl Pind; Michael Borre; Theis Lange
Journal:  Sex Med       Date:  2018-07-13       Impact factor: 2.491

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.